BeyondSpring (BYSI) Stock Forecast, Price & News

BeyondSpring (NASDAQ:BYSI) Frequently Asked Questions

Is BeyondSpring a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BeyondSpring in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BeyondSpring stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BYSI, but not buy additional shares or sell existing shares.
View analyst ratings for BeyondSpring or view top-rated stocks.

When is BeyondSpring's next earnings date?

BeyondSpring is scheduled to release its next quarterly earnings announcement on Wednesday, June 15th 2022.
View our earnings forecast for BeyondSpring.

How were BeyondSpring's earnings last quarter?

BeyondSpring Inc. (NASDAQ:BYSI) posted its quarterly earnings data on Thursday, April, 14th. The company reported ($0.24) earnings per share for the quarter. The company earned $0.34 million during the quarter. BeyondSpring had a negative net margin of 4,750.48% and a negative trailing twelve-month return on equity of 144.52%.
View BeyondSpring's earnings history.

What price target have analysts set for BYSI?

6 brokers have issued 12 month price targets for BeyondSpring's stock. Their forecasts range from $5.00 to $65.00. On average, they expect BeyondSpring's share price to reach $30.00 in the next twelve months. This suggests a possible upside of 2,300.0% from the stock's current price.
View analysts' price targets for BeyondSpring or view top-rated stocks among Wall Street analysts.

Who are BeyondSpring's key executives?

BeyondSpring's management team includes the following people:

• Dr. Lan Huang, Co-Founder, Chairman & CEO (Age 51)
• Ms. Elizabeth Adkins Czerepak, Exec. VP & CFO (Age 66)
• Dr. G. Kenneth Lloyd, Chief Scientific Officer (Age 78)
• Dr. Ramon W. Mohanlal, Exec. VP of R&D, Chief Medical Officer and Director (Age 64)
• Dr. Gordon L. Schooley, Chief Regulatory Officer (Age 75)
• Mr. Linqing Jia, Co-Founder
• Stephen Kilmer, Head of Investor Relations
• Mr. Gregg Russo, Sr. VP of HR

Who are some of BeyondSpring's key competitors?

Some companies that are related to BeyondSpring include Nanobiotix (NBTX), Entrada Therapeutics (TRDA), Harrow Health (HROW), Immunic (IMUX), Omeros (OMER), Pliant Therapeutics (PLRX), Oramed Pharmaceuticals (ORMP), XBiotech (XBIT), Theratechnologies (THERF), Viking Therapeutics (VKTX), Verrica Pharmaceuticals (VRCA), Rezolute (RZLTD), Clene (CLNN), Rhythm Pharmaceuticals (RYTM) and LumiraDx (LMDX).
View all of BYSI's competitors.

What other stocks do shareholders of BeyondSpring own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BeyondSpring investors own include Exelixis (EXEL), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Enterprise Products Partners (EPD), Johnson & Johnson (JNJ), Pfizer (PFE), Atara Biotherapeutics (ATRA), CorMedix (CRMD) and Dynavax Technologies (DVAX).

When did BeyondSpring IPO?

(BYSI) raised $4 million in an initial public offering on Thursday, March 9th 2017. The company issued 200,000 shares at a price of $20.00 per share. Rodman & Renshaw (a Unit of H.C. Wainwright & Co.) served as the underwriter for the IPO.

What is BeyondSpring's stock symbol?

BeyondSpring trades on the NASDAQ under the ticker symbol "BYSI."

Who are BeyondSpring's major shareholders?

BeyondSpring's stock is owned by a variety of retail and institutional investors. Top institutional investors include Decheng Capital Management III Cayman LLC (12.74%), BlackRock Inc. (4.78%), State Street Corp (1.45%), Renaissance Technologies LLC (0.73%), Northern Trust Corp (0.42%) and BNP Paribas Arbitrage SA (0.34%).

Which institutional investors are selling BeyondSpring stock?

BYSI stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Simplex Trading LLC, Jane Street Group LLC, Group One Trading L.P., and Northern Trust Corp.

Which institutional investors are buying BeyondSpring stock?

BYSI stock was bought by a variety of institutional investors in the last quarter, including Decheng Capital Management III Cayman LLC, BlackRock Inc., Renaissance Technologies LLC, XTX Topco Ltd, State Street Corp, Acadian Asset Management LLC, Hennion & Walsh Asset Management Inc., and BNP Paribas Arbitrage SA.

How do I buy shares of BeyondSpring?

Shares of BYSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BeyondSpring's stock price today?

One share of BYSI stock can currently be purchased for approximately $1.25.

How much money does BeyondSpring make?

BeyondSpring has a market capitalization of $48.66 million and generates $1.35 million in revenue each year. The company earns $-64.18 million in net income (profit) each year or ($1.640010) on an earnings per share basis.

How many employees does BeyondSpring have?

BeyondSpring employs 91 workers across the globe.

What is BeyondSpring's official website?

The official website for BeyondSpring is www.beyondspringpharma.com.

How can I contact BeyondSpring?

BeyondSpring's mailing address is 28 LIBERTY STREET 39TH FLOOR, NEW YORK NY, 10005. The company can be reached via phone at (646) 305-6387, via email at [email protected], or via fax at 1-646-882-4228.